Home Healthcare Pharmaceuticals KRAS Inhibitor Market

KRAS Inhibitor Market Size, Share & Trends Analysis Report By Type (KRAS G12C Inhibitors, KRAS G12D Inhibitors, Others), By Drug (Sotorasib, Adagrasib, Fulzerasib, Garsorasib), By Disease Indication (Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer, Others), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Drug Stores & Retail Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 24, 2026 | Author: Debashree Bora | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. KRAS Inhibitor Market, By Type 2022-2034 (USD MILLION/ Units)
    1. KRAS G12C Inhibitors
    2. KRAS G12D Inhibitors
    3. Others
  2. KRAS Inhibitor Market, By Drug 2022-2034 (USD MILLION/ Units)
    1. Sotorasib
    2. Adagrasib
    3. Fulzerasib
    4. Garsorasib
  3. KRAS Inhibitor Market, By Disease Indication 2022-2034 (USD MILLION/ Units)
    1. Non-small Cell Lung Cancer
    2. Colorectal Cancer
    3. Pancreatic Cancer
    4. Biliary Tract Cancer
    5. Others
  4. KRAS Inhibitor Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Specialty Pharmacies
    3. Drug Stores & Retail Pharmacies
  5. Regional KRAS Inhibitor Market
    1. North America
      1. North America KRAS Inhibitor Market By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      2. North America KRAS Inhibitor Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      3. North America KRAS Inhibitor Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      4. North America KRAS Inhibitor Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
      5. U.S.
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      6. Canada
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
    2. Europe
      1. Europe KRAS Inhibitor Market By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      2. Europe KRAS Inhibitor Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      3. Europe KRAS Inhibitor Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      4. Europe KRAS Inhibitor Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
      5. U.K.
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      6. Germany
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      7. France
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      8. Spain
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      9. Italy
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      10. Russia
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      11. Nordic
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      12. Benelux
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      13. Rest of Europe
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
    3. APAC
      1. APAC KRAS Inhibitor Market By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      2. APAC KRAS Inhibitor Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      3. APAC KRAS Inhibitor Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      4. APAC KRAS Inhibitor Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
      5. China
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      6. Korea
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      7. Japan
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      8. India
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      9. Australia
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      10. Taiwan
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      11. South East Asia
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      12. Rest of Asia-Pacific
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
    4. Middle East and Africa
      1. Middle East and Africa KRAS Inhibitor Market By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      2. Middle East and Africa KRAS Inhibitor Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      3. Middle East and Africa KRAS Inhibitor Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      4. Middle East and Africa KRAS Inhibitor Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
      5. UAE
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      6. Turkey
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      7. Saudi Arabia
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      8. South Africa
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      9. Egypt
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      10. Nigeria
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      11. Rest of MEA
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
    5. LATAM
      1. LATAM KRAS Inhibitor Market By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      2. LATAM KRAS Inhibitor Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      3. LATAM KRAS Inhibitor Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      4. LATAM KRAS Inhibitor Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
      5. Brazil
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      6. Mexico
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      7. Argentina
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      8. Chile
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      9. Colombia
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
      10. Rest of LATAM
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
        4. Sotorasib
        5. Adagrasib
        6. Fulzerasib
        7. Garsorasib
        8. Non-small Cell Lung Cancer
        9. Colorectal Cancer
        10. Pancreatic Cancer
        11. Biliary Tract Cancer
        12. Others
        13. Hospital Pharmacies
        14. Specialty Pharmacies
        15. Drug Stores & Retail Pharmacies
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.